Exencial Wealth Advisors LLC Decreases Stock Holdings in Humana Inc. (NYSE:HUM)

Exencial Wealth Advisors LLC trimmed its holdings in shares of Humana Inc. (NYSE:HUM) by 3.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 8,018 shares of the insurance provider’s stock after selling 302 shares during the period. Exencial Wealth Advisors LLC’s holdings in Humana were worth $2,034,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Creative Financial Designs Inc. ADV increased its position in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares during the last quarter. FPC Investment Advisory Inc. purchased a new stake in Humana in the fourth quarter worth $27,000. Centricity Wealth Management LLC purchased a new stake in Humana in the fourth quarter worth $30,000. Ashton Thomas Securities LLC purchased a new stake in Humana in the third quarter worth $31,000. Finally, Atwood & Palmer Inc. increased its position in Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

NYSE:HUM opened at $263.74 on Wednesday. The firm has a market capitalization of $31.82 billion, a price-to-earnings ratio of 26.51, a P/E/G ratio of 2.05 and a beta of 0.57. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The stock has a fifty day moving average of $271.40 and a 200 day moving average of $285.08. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.34%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is currently 35.58%.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on HUM shares. Barclays raised their target price on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. decreased their target price on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and raised their price target for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 price target on shares of Humana in a report on Wednesday, February 12th. Finally, Truist Financial raised their price target on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Twenty research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.